SCHEMBL1504522

SCHEMBL1504522

O=C(Nc1cc(C(=O)NC2CC2)ccc1Cl)c1ccc(=O)n(-c2cccc(F)c2F)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 16/20 0.49
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 1/20 0.47
CYP1A2 P05177 1/20 0.45
MAPK11 Q15759 1/20 0.45
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
MAPKAPK2 P49137 1/20 0.43
MAPK13 O15264 1/20 0.42
F10 P00742 1/20 0.42
TP53 P04637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1504506 0.90 MAPK14 (0.56) MAPK14KDM4EMEN1POLBMAPT
SCHEMBL1504707 0.88 HDAC1 (0.43) MEN1MAPTKMT2ACYP2C9CYP2C19
SCHEMBL1504459 0.88 MAPK14 (0.54) MAPK14KDM4EMEN1POLBMAPT
SCHEMBL1504630 0.84 KDM4E (0.52) MAPK14KDM4EMEN1POLBMAPT
SCHEMBL1504706 0.80 MAPK14 (0.48) MAPK14KDM4EMEN1POLBMAPT
SCHEMBL2673907 0.80 MAPK14 (0.48) MAPK14KDM4EMEN1POLBMAPT
SCHEMBL1504734 0.80 MAPK14 (0.53) MAPK14MAPK11MAPKAPK2MAPK13
SCHEMBL1504726 0.79 KDM4E (0.50) MAPK14KDM4EMEN1POLBMAPT
SCHEMBL10042723 0.78 KDM4E (0.52) MAPK14KDM4EMEN1POLBMAPT
SCHEMBL1504478 0.78 MAPK14 (0.56) MAPK14MAPK11MAPKAPK2MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173684-B2 Pyridone derivatives as p38α MAPK inhibitors ASTELLAS PHARMA INC. (JP) 2012-05-08 US disclosed
US-8173684-B2 Pyridone derivatives as p38α MAPK inhibitors ASTELLAS PHARMA INC. (JP) 2012-05-08 US disclosed
US-8173684-B2 Pyridone derivatives as p38α MAPK inhibitors ASTELLAS PHARMA INC. (JP) 2012-05-08 US disclosed
EP-2155683-B1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS ASTELLAS PHARMA INC (JP) 2011-03-16 EP disclosed
US-20100063098-A1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS ASTELLAS PHARMA INC. (JP) 2010-03-11 US disclosed
US-20100063098-A1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS ASTELLAS PHARMA INC. (JP) 2010-03-11 US disclosed
US-20100063098-A1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS ASTELLAS PHARMA INC. (JP) 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063098-A1 PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS MAPK1, MAPK6, MAPK3 MAPK14 25/4885KDM4E 1656/4885MEN1 4446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.